Latest Commercialisation Strategy News

Orthocell has achieved its first commercial sales of Remplir™ in Hong Kong, marking a pivotal step in its Asian growth strategy and expanding its footprint across key global markets.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

I Synergy Group’s subsidiary has inked four separate 12-month leases for its AI computing hardware and software, marking a strategic push into recurring revenue streams.

New Frontier Minerals has locked in a decade-long exclusive agreement with Metallium to apply cutting-edge Flash Joule Heating technology to its Harts Range ore, achieving unprecedented rare earth enrichment. This partnership targets strategic US defense and magnet markets, marking a pivotal step for the project’s commercial future.

Archer Materials has partnered with CSIRO to develop cutting-edge quantum machine learning models aimed at revolutionizing fraud detection in financial transactions.

Sparc Technologies teams up with Dulux Australia to apply their graphene-enhanced ecosparc® coating on the heritage-listed Cape Jaffa Lighthouse, marking a key step in commercialising advanced protective coatings.

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.

Green Critical Minerals has signed a landmark MoU with South Korea’s Komex Carbon Corporation to co-develop and commercialize Very High Density (VHD) carbon products, marking GCM’s first international commercial agreement and a key step toward revenue generation in 2026.

Orthocell has completed its first Remplir™ surgical case in Hong Kong, marking a pivotal step in its Asian commercialisation strategy. The launch at the Hong Kong Orthopaedic Association Congress and partnership with MontsMed set the stage for broader regional growth.

FBR Limited unveiled its new DST-enabled Mantis welding robot targeting heavy fabrication sectors while completing key milestones on its Hadrian bricklaying technology and securing a $22 million financing package.

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.